NHS England invites cladribine suppliers to framework procurement worth £61.2m
The health service is signalling its intention to establish a national framework agreement for cladribine tablets and has opened market engagement to potential suppliers.
Written with data automation, reviewed by the editor · Published
NHS England has published a planned procurement notice for a national framework agreement on cladribine tablets, valued at an estimated £61.2m. The notice invites suppliers planning to introduce the molecule to contact the MPSC New Market Developments Team ahead of a formal tender process.
Key facts
buyer
NHS England
value
£61.2m (estimated)
supplier
Not yet appointed
published
3 July 2026
procedure or type
Planned procurement notice; national framework agreement
NHS England is preparing the ground for a significant medicines procurement by opening early engagement with suppliers interested in cladribine tablets.
The planned procurement notice signals the buyer's intention to establish a national framework agreement for the molecule. The estimated value of the framework is £61.2m. Suppliers with plans to bring cladribine tablets to market, or with questions about the upcoming exercise, are invited to contact the MPSC New Market Developments Team directly ahead of any formal tender.
The framework device allows NHS England to establish terms and conditions with one or more suppliers, then place individual orders (call-offs) as required during the agreement period, rather than running separate full tenders for each purchase.
A planned procurement notice is a market-signalling tool. It does not trigger a formal tender deadline; instead, it opens a dialogue between the buyer and the supply market. Interested suppliers should contact the MPSC team at the email addresses provided to register interest and seek clarification on the scope and timing of the formal procurement exercise.